These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 29498049)

  • 1. Red blood cells treated with the amustaline (S-303) pathogen reduction system: a transfusion study in cardiac surgery.
    Brixner V; Kiessling AH; Madlener K; Müller MM; Leibacher J; Dombos S; Weber I; Pfeiffer HU; Geisen C; Schmidt M; Henschler R; North A; Huang N; Mufti N; Erickson A; Ernst C; Rico S; Benjamin RJ; Corash LM; Seifried E
    Transfusion; 2018 Apr; 58(4):905-916. PubMed ID: 29498049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study.
    Cancelas JA; Gottschall JL; Rugg N; Graminske S; Schott MA; North A; Huang N; Mufti N; Erickson A; Rico S; Corash L
    Vox Sang; 2017 Apr; 112(3):210-218. PubMed ID: 28220519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the efficacy and safety of amustaline/glutathione pathogen-reduced RBCs in complex cardiac surgery: the Red Cell Pathogen Inactivation (ReCePI) study-protocol for a phase 3, randomized, controlled trial.
    Snyder EL; Sekela ME; Welsby IJ; Toyoda Y; Alsammak M; Sodha NR; Beaver TM; Pelletier JPR; Gorham JD; McNeil JS; Sniecinski RM; Pearl RG; Nuttall GA; Sarode R; Reece TB; Kaplan A; Davenport RD; Ipe TS; Benharash P; Lopez-Plaza I; Gammon RR; Sadler P; Pitman JP; Liu K; Bentow S; Corash L; Mufti N; Varrone J; Benjamin RJ;
    Trials; 2023 Dec; 24(1):799. PubMed ID: 38082326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical safety assessment of pathogen reduced red blood cells treated with amustaline and glutathione.
    North AK; Mufti N; Sullivan T; Corash L
    Transfusion; 2020 Feb; 60(2):358-366. PubMed ID: 31930533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Red blood cell in vitro quality and function is maintained after S-303 pathogen inactivation treatment.
    Winter KM; Johnson L; Kwok M; Vidovic D; Hyland RA; Mufti N; Erickson A; Marks DC
    Transfusion; 2014 Jul; 54(7):1798-807. PubMed ID: 24617658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients.
    Benjamin RJ; McCullough J; Mintz PD; Snyder E; Spotnitz WD; Rizzo RJ; Wages D; Lin JS; Wood L; Corash L; Conlan MG
    Transfusion; 2005 Nov; 45(11):1739-49. PubMed ID: 16271099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogen inactivation of Dengue virus in red blood cells using amustaline and glutathione.
    Aubry M; Laughhunn A; Santa Maria F; Lanteri MC; Stassinopoulos A; Musso D
    Transfusion; 2017 Dec; 57(12):2888-2896. PubMed ID: 28921542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of natural and acquired antibodies to amustaline/glutathione pathogen reduced red blood cells.
    Geisen C; North A; Becker L; Brixner V; von Goetz M; Corash L; Benjamin RJ; Mufti N; Seifried E
    Transfusion; 2020 Oct; 60(10):2389-2398. PubMed ID: 32692456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivation of Plasmodium falciparum in whole blood using the amustaline and glutathione pathogen reduction technology.
    Sow C; Laughhunn A; Girard YA; Lanteri MC; Amar El Dusouqui S; Stassinopoulos A; Grellier P
    Transfusion; 2020 Apr; 60(4):799-805. PubMed ID: 32129497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivation of chikungunya virus in blood components treated with amotosalen/ultraviolet A light or amustaline/glutathione.
    Laughhunn A; Huang YS; Vanlandingham DL; Lanteri MC; Stassinopoulos A
    Transfusion; 2018 Mar; 58(3):748-757. PubMed ID: 29322519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process.
    Cancelas JA; Dumont LJ; Rugg N; Szczepiorkowski ZM; Herschel L; Siegel A; Pratt PG; Worsham DN; Erickson A; Propst M; North A; Sherman CD; Mufti NA; Reed WF; Corash L
    Transfusion; 2011 Nov; 51(11):2367-76. PubMed ID: 21569044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amustaline (S-303) treatment inactivates high levels of Chikungunya virus in red-blood-cell components.
    Aubry M; Laughhunn A; Santa Maria F; Lanteri MC; Stassinopoulos A; Musso D
    Vox Sang; 2018 Apr; 113(3):232-241. PubMed ID: 29314033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amustaline (S-303) treatment inactivates high levels of Zika virus in red blood cell components.
    Laughhunn A; Santa Maria F; Broult J; Lanteri MC; Stassinopoulos A; Musso D; Aubry M
    Transfusion; 2017 Mar; 57(3pt2):779-789. PubMed ID: 28164306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robust inactivation of Plasmodium falciparum in red blood cell concentrates using amustaline and glutathione pathogen reduction.
    Sow C; Bouissou A; Girard YA; Singh GB; Bounaadja L; Payrat JM; Haas D; Isola H; Lanteri MC; Bringmann P; Grellier P
    Transfusion; 2022 May; 62(5):1073-1083. PubMed ID: 35385146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical pharmacokinetic and toxicology assessment of red blood cells prepared with S-303 pathogen inactivation treatment.
    North A; Ciaravino V; Mufti N; Corash L
    Transfusion; 2011 Oct; 51(10):2208-18. PubMed ID: 21985050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemia.
    Aydinok Y; Piga A; Origa R; Mufti N; Erickson A; North A; Waldhaus K; Ernst C; Lin JS; Huang N; Benjamin RJ; Corash L
    Br J Haematol; 2019 Aug; 186(4):625-636. PubMed ID: 31148155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraoperative Anemia and Single Red Blood Cell Transfusion During Cardiac Surgery: An Assessment of Postoperative Outcome Including Patients Refusing Blood Transfusion.
    Hogervorst EK; Rosseel PM; van de Watering LM; Brand A; Bentala M; van der Bom JG; van der Meer NJ
    J Cardiothorac Vasc Anesth; 2016 Apr; 30(2):363-72. PubMed ID: 26809765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pathogen-reduced red blood cell suspension: single centre study of clinical safety and efficacy in children with oncological and haematological diseases.
    Trakhtman P; Kumukova I; Starostin N; Borsakova D; Balashov D; Ignatova A; Kadaeva L; Novichkova G; Rumiantcev A
    Vox Sang; 2019 Apr; 114(3):223-231. PubMed ID: 30784069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of storage of red blood cells on the development of postoperative infections after noncardiac surgery.
    Spadaro S; Taccone FS; Fogagnolo A; Fontana V; Ragazzi R; Verri M; Valpiani G; Greco P; Bianconi M; Govoni M; Reverberi R; Volta CA
    Transfusion; 2017 Nov; 57(11):2727-2737. PubMed ID: 28782123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longer RBC storage duration is associated with increased postoperative infections in pediatric cardiac surgery.
    Cholette JM; Pietropaoli AP; Henrichs KF; Alfieris GM; Powers KS; Phipps R; Spinelli SL; Swartz M; Gensini F; Daugherty LE; Nazarian E; Rubenstein JS; Sweeney D; Eaton M; Blumberg N
    Pediatr Crit Care Med; 2015 Mar; 16(3):227-35. PubMed ID: 25607740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.